Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-4642 + cetuximab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**HRS-4642 + cetuximab** is a combination investigational therapy comprised of HRS-4642, a selective long-acting KRAS G12D inhibitor formulated as a liposomal injection, and cetuximab, an epidermal growth factor receptor (EGFR) monoclonal antibody. HRS-4642 inhibits mutant KRAS G12D, suppressing downstream MEK/ERK phosphorylation to block tumor cell proliferation. Cetuximab antagonizes EGFR-mediated signaling, counteracting adaptive feedback resistance commonly triggered by KRAS inhibition. The combination aims to improve efficacy in advanced solid tumors, especially pancreatic ductal adenocarcinoma (PDAC) with KRAS G12D mutations that are refractory to standard therapies.[1][3][5]
- Other names
- HRS-4642 + cetuximabHRS-4642 plus cetuximabHRS4642 plus cetuximabHRS 4642 plus cetuximabErbitux (for cetuximab)
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)
Beyond the preview
Go deeper on HRS-4642 + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-4642 + cetuximab.